Adverse Reactions to Selective Cyclooxygenase-2 Inhibitors (Coxibs)

作者: Mario S??nchez-Borges , Arnaldo Capriles-Hulett , Fernan Caballero-Fonseca

DOI: 10.1097/01.MJT.0000125121.35422.B4

关键词: DrugMedical prescriptionAspirinPharmacologyPatient managementAsthmaAnalgesicAntipyreticCyclooxygenaseMedicinePharmacology (medical)General Medicine

摘要: Coxibs, selective inhibitors of arachidonic acid cyclooxygenase-2, constitute a new, clinically useful therapeutic class drugs that possess analgesic, antiinflammatory, and antipyretic properties. The drug inserts prescription information presently provide warning contraindicating their use in patients with aspirin-intolerant asthma aspirin NSAID hypersensitivity. However, according to investigations reported until now, most those NSAID-sensitive individuals will tolerate coxibs. Careful oral challenge is for patient management since some cutaneous systemic reactions hypersensitivity, especially when sulfonamide-containing coxibs are employed, may occur.

参考文章(39)
A Szczeklik, The cyclooxygenase theory of aspirin-induced asthma European Respiratory Journal. ,vol. 3, pp. 588- 593 ,(1990)
C C Chan, I W Rodger, Y Girard, D Riendeau, J P Falgueyret, C Brideau, D Ethier, M Gresser, R W Friesen, E Wong, S Boyce, M D Percival, D Dubé, P Prasit, D Visco, A W Ford-Hutchinson, J Mancini, S Charleson, G Greig, J Guay, R Zamboni, M Ouellet, L Xu, R N Young, R Gordon, Etoricoxib (MK-0663): Preclinical Profile and Comparison with Other Agents That Selectively Inhibit Cyclooxygenase-2 Journal of Pharmacology and Experimental Therapeutics. ,vol. 296, pp. 558- 566 ,(2001)
Michael B. Levy, Jordan N. Fink, Anaphylaxis to celecoxib Annals of Allergy Asthma & Immunology. ,vol. 87, pp. 72- 73 ,(2001) , 10.1016/S1081-1206(10)62327-7
Kenneth H. Fye, Eileen Crowley, Timothy G. Berger, Philip E. LeBoit, M.Kari Connolly, Celecoxib-induced Sweet's syndrome Journal of The American Academy of Dermatology. ,vol. 45, pp. 300- 302 ,(2001) , 10.1067/MJD.2001.114587
M. Grob, W.J. Pichler, B. Wuthrich, Anaphylaxis to celecoxib Allergy. ,vol. 57, pp. 264- 265 ,(2002) , 10.1034/J.1398-9995.2002.1N3581.X
M. L. Pacor, G. Di Lorenzo, D. Biasi, M. Barbagallo, R. Corrocher, Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs. Clinical & Experimental Allergy. ,vol. 32, pp. 397- 400 ,(2002) , 10.1046/J.1365-2222.2002.01260.X
MP Berges-Gimeno, E Camacho-Garrido, RM Garcia-Rodriguez, T Alfaya, C Martin Garcia, M Hinojosa, None, Rofecoxib safe in NSAID hypersensitivity. Allergy. ,vol. 56, pp. 1017- 1018 ,(2001) , 10.1034/J.1398-9995.2001.00206.X
Eustachio Nettis, Roberto Di Paola, Antonio Ferrannini, Alfredo Tursi, Tolerability of rofecoxib in patients with cutaneous adverse reactions to nonsteroidal anti-inflammatory drugs Annals of Allergy Asthma & Immunology. ,vol. 88, pp. 331- 334 ,(2002) , 10.1016/S1081-1206(10)62017-0
Denise L. Glasser, Susan H. Burroughs, Valdecoxib-induced toxic epidermal necrolysis in a patient allergic to sulfa drugs. Pharmacotherapy. ,vol. 23, pp. 551- 553 ,(2003) , 10.1592/PHCO.23.4.551.32118
Garret A. FitzGerald, Carlo Patrono, The coxibs, selective inhibitors of cyclooxygenase-2. The New England Journal of Medicine. ,vol. 345, pp. 433- 442 ,(2001) , 10.1056/NEJM200108093450607